| 2016-10-18 08:34:21|
NERV 08:34 10/18 10/18/16
Minerva poised to report positive data, says JMP Securities
JMP Securities analyst Jason Butler expects Phase 2b data on Minerva's MIN-101 drug for schizophrenia to be positive when it's reported this month. The analyst thinks that the data could include evidence that the drug "maintains control of positive symptoms." He reiterates a $17 price target and Outperform rating on the shares.